The 25.6 Data Release includes updates to human and model studies, including NPS-AD and MARMO-AD studies

Human

  • The Emory_Levey_300_CSF_FNIH Study

    This study provides a proteomic network analysis of Alzheimer’s Disease cerebrospinal fluid sourced from individuals in the Emory_ADRC cohort. 

    • This release provides raw files, search/quantification results, analysis scripts, outputs of these scripts, and specimen-level clinical metadata for approximately 370 individuals.

  • The NPS-AD Study

    This study provides single-nucleus RNAseq profiles from the dorsolateral prefrontal cortex of 1494 donors from the Mt Sinai Brain Bank, NIMH Human Brain Collection Core, and ROSMAP cohorts. In addition to Alzheimer’s Disease status, information on the presence of other dementias or neuropsychiatric conditions is also provided.

    • This release provides processed h5ad cell count matrices for all samples and updated clinical metadata.

  • The CD74-IHC Study

    This study measures amyloid load and PHF Tau tangles in participants from the ROS and MAP cohorts using immunocytochemistry, image analysis, and stereology.

    • This release provides immunofluorescence data sourced from dorsolateral prefrontal cortex samples.

Models

  • The Jax.IU.LOAD2 Study

    The LOAD2 mouse model, developed by the MODEL‑AD Consortium is a homozygous model designed to better reflect genetic and environmental risk factors of late‑onset Alzheimer’s disease (LOAD). It integrates three key humanized risk elements: 

    • Human APOE4 allele – the strongest genetic risk factor for LOAD.
    • TREM2 R47H variant – alters microglial response and is associated with increased disease risk.
    • Humanized amyloid‑beta (Aβ) sequence – replacing the mouse App Aβ region with the human form, which is inherently more amyloidogenic.

    This study includes gene × environment interactions by using a high-fat diet (HFD) to induce phenotypes in the LOAD2 model, effectively resembling the metabolic risk factors that contribute to Alzheimer’s disease in humans. Comprehensive phenotyping: Includes multi-modal datasets—behavioral, molecular (omics), and imaging/immunoassay.

  • The UCI_Apoe_Christchurch Study

    This study provides immunohistochemistry, biochemistry, blood chemistry and plasma neurofilament light chain (NfL) data from transgenic mouse models designed to investigate the effects of the human APOE Christchurch (ApoeCh) variant. The dataset includes animals from both amyloid and tau model cohorts (5xFAD and PS19, respectively) at several timepoints.

    • This release includes quantitative MSD electrochemoluminiscence, immunohistochemistry data for plasma NfL levels.

  • The UCI_Clu-h2kbKI_RNAseq Study
    This study provides bulk RNA sequencing data for the Clu-h2KbKI variant to investigate the impact of the rs2279590 human CLU allele on Alzheimer’s disease pathology. Mice used in this study include wild-type (C57BL/6J), 5xFAD hemizygous, Clu-h2kbKI homozygous, and compound 5xFAD;Clu-h2kbKI hemizygous genotypes. Data were generated from both hippocampus and cortex tissue collected at 4 and 12 months of age.

  • The MARMO-AD Study

    This study aims to generate, characterize, and validate marmoset models of Alzheimer’s Disease. This study aims to generate, characterize, and validate the marmoset as a non-human primate model of aging and Alzheimer’s Disease. This release provides data from over 400 animals, including metadata, plasma biomarkers, brain proteomes and transcriptomes, fibroblast proteomes and transcriptomes, cognitive test scores, and infant assessments.